Author

A. Biankin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Assay:spatial transcriptomics· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Agostini· 1 shared A. Caggiano· 1 shared A. Cameron· 1 shared A. DeFazio· 1 shared A. Esposito· 1 shared A. Larghi· 1 shared A. Legrini· 1 shared A. Papenfuss· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Agostini

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Transcriptomic dissection of Intraepithelial Papillary Mucinous Neoplasms progression by spatial technologies identified novel markers of pancreatic carcinogenesis.

A. Agostini, G. Piro, F. Inzani, G. Quero, A. Esposito, A. Caggiano, L. Priori, A. Larghi, S. Alfieri, R. Casolino, V. Corbo, A. Biankin, G. Tortora, C. Carbone

This study uses spatial transcriptomics to identify novel markers and mechanisms of IPMN progression to PDAC, revealing distinct cell clusters and transcription factors associated with different grades of malignancy.

bioRxiv · Oct 12, 2022 · PreprintCancer Biology

Spatially Resolved Transcriptomics Deconvolutes Histological Prognostic Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases

C. S. Wood, K. Pennel, H. Leslie, A. Legrini, A. Cameron, L. Melissourgou-Syka, J. Quinn, H. Van Wyk, J. Hay, A. Roseweir, C. Nixon, C. Roxburgh, D. McMillan, A. Biankin, O. J. Sansom, , N. Jamieson

This study uses spatial transcriptomics to identify prognostic immune and stromal subgroups in colorectal cancer liver metastases, revealing distinct transcriptomic programs associated with survival outcomes.

bioRxiv · Sep 21, 2022 · PreprintCancer Biology

Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

G. Y. Ho, E. Kyran, J. Bedo, M. Wakefield, D. Ennis, H. Mirza, S. Cooke, E. Lieschke, C. Vandenberg, O. Kondrashova, R. Upstill-Goddard, U.-M. Bailey, S. Biankin, P. Roxburgh, R. Glasspool, , H. Barker

This study identifies N-MYC pathway activation and susceptibility to EMT-targeting therapy in ovarian carcinosarcoma using genomic and pre-clinical models.

bioRxiv · Nov 24, 2020 · PreprintCancer Biology

An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer

C.-H. Pan, Y. Otsuka, B. Sridharan, M. Woo, S. Babu, C. V. Leiton, J. D. Bai, D. K. Chang, A. Biankin, L. Scampavia, T. Spicer, L. F. Escobar-Hoyos, K. R. Shroyer

This study identifies K17 as a biomarker for PDAC and shows that PPT, a microtubule inhibitor, is more effective against K17-expressing PDAC cells when combined with Gemcitabine.

bioRxiv · Oct 11, 2019Cancer Biology

Macrophage Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer

C. J. Halbrook, C. Pontious, H.-J. Lee, I. Kovalenko, Y. Zhang, L. Lapienyte, S. Dreyer, D. M. Kremer, P. Sajjakulnukit, L. Zhang, B. Nelson, H. Hong, S. Kemp, D. Chang, A. Biankin, , C. A. Lyssiotis

This study shows macrophages in pancreatic cancer release pyrimidines that inhibit gemcitabine therapy by competing with the drug for uptake and metabolism, and reducing macrophage burden improves treatment response.

bioRxiv · Nov 5, 2018Cancer Biology